Othman TA - Search Results

1

Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents.

Othman TA, Mei M, Zhang J, Aldoss I, Stein A, Forman SJ, Marcucci G, Pullarkat V. Othman TA, et al. Am J Hematol. 2021 May 1;96(5):E140-E143. doi: 10.1002/ajh.26117. Epub 2021 Feb 18. Am J Hematol. 2021. PMID: 33524204 Free article. No abstract available.

2

Characteristics and Trends of Adult Acute Lymphoblastic Leukemia in a Large, Public Safety-Net Hospital.

Gupta R, Othman T, Uche A, Amanam I, Chen C, Celles L, Lane G, Mei M, Aldoss I, Pullarkat V, Kim P, Yeh J. Gupta R, et al. Clin Lymphoma Myeloma Leuk. 2020 Jun;20(6):e320-e327. doi: 10.1016/j.clml.2019.11.003. Epub 2020 Feb 28. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32199763 Clinical Trial.

3

Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy.

Othman TA, Zhang J, Mei M, Stein AS, Forman SJ, Marcucci G, Pullarkat V, Aldoss I. Othman TA, et al. Leuk Lymphoma. 2020 Dec;61(14):3532-3533. doi: 10.1080/10428194.2020.1808213. Epub 2020 Aug 19. Leuk Lymphoma. 2020. PMID: 32811233 No abstract available.

4

Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?

Othman T, Herrera A, Mei M. Othman T, et al. Curr Hematol Malig Rep. 2021 Feb;16(1):1-7. doi: 10.1007/s11899-020-00603-3. Epub 2021 Jan 6. Curr Hematol Malig Rep. 2021. PMID: 33409966 Review.

5

Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.

Othman TA, Azenkot T, Moskoff BN, Tenold ME, Jonas BA. Othman TA, et al. Future Oncol. 2021 Aug;17(23):2989-3005. doi: 10.2217/fon-2021-0262. Epub 2021 May 24. Future Oncol. 2021. PMID: 34024158 Review.

6

An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.

Othman TA, Tenold ME, Moskoff BN, Azenkot T, Jonas BA. Othman TA, et al. Expert Rev Hematol. 2021 May;14(5):407-417. doi: 10.1080/17474086.2021.1938533. Epub 2021 Jun 15. Expert Rev Hematol. 2021. PMID: 34076549 Free PMC article. Review.

7

Role of Salvage Radiation Treatment of Relapses in Relapsed/Refractory Diffuse Large B Cell Lymphoma Post-Autologous Stem Cell Transplant.

Ladbury C, Thiruvengadam SK, Othman T, Hao C, Chen L, Wong J, Cao T, Herrera A, Mei M, Dandapani S. Ladbury C, et al. Int J Radiat Oncol Biol Phys. 2022 Jul 1;113(3):594-601. doi: 10.1016/j.ijrobp.2022.02.015. Epub 2022 Feb 15. Int J Radiat Oncol Biol Phys. 2022. PMID: 35176414

8

Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma.

Othman T, Baird JH, Pak S, Mei M, Herrera AF, Mansour J, Shouse G, Sahebi F, Spielberger R, Cai JL, Farol L, Godfrey J, Kallam A, Phillips T, Popplewell L, Siddiqi T, Forman S, Budde LE. Othman T, et al. Br J Haematol. 2024 Jul;205(1):368-372. doi: 10.1111/bjh.19521. Epub 2024 May 26. Br J Haematol. 2024. PMID: 38797530 No abstract available.

9

Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Othman T, Li S, Zhang J, Pourhassan H, Agrawal V, Ngo D, Chen J, Farol L, Sahebi F, Sandhu K, Spielberger R, Marcucci G, Forman SJ, Stein AS, Nakamura R, Pullarkat V, Mei M, Aldoss I, Koller P. Othman T, et al. Am J Hematol. 2024 Aug;99(8):1636-1639. doi: 10.1002/ajh.27365. Epub 2024 May 27. Am J Hematol. 2024. PMID: 38800943

10

Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Othman T, Koller P, Tsai NC, Yang D, Pourhassan H, Agrawal V, Ngo D, Chen J, Farol L, Spielberger R, Sahebi F, Al Malki MM, Cai JL, Sandhu KS, Mansour J, Salhotra A, Ali H, Aribi A, Arslan S, Marcucci G, Forman SJ, Stein AS, Nakamura R, Pullarkat V, Aldoss I, Mei M. Othman T, et al. Am J Hematol. 2024 Sep;99(9):1680-1690. doi: 10.1002/ajh.27378. Epub 2024 May 28. Am J Hematol. 2024. PMID: 38804599

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26 results

Search Page

Filters